Enliven Therapeutics (ELVN) affiliate notifies broker to offer 18,054 shares

Rhea-AI Filing Summary

Enliven Therapeutics filed a Form 144 reporting the proposed sale of 18,054 shares of Common Stock through Jefferies LLC, dated 06/17/2026. The notice lists three lots tied to option exercises: 7,090, 3,000, and 7,964 shares with exercise dates shown as 08/09/2022, 12/13/2024, and 03/04/2025, respectively.

The filing identifies Jefferies LLC at 520 Madison Ave as the broker-dealer and shows an aggregate value field of $768,197.70 on the cover line. The filing is a routine Section 16 disposition notice for resale of shares previously acquired by option exercise.

Insights

Securities Compliance Specialist

Form 144 documents a planned resale of shares by an insider or affiliate via broker-dealer.

The filing lists 18,054 shares offered for sale in three lots tied to prior option exercises dated 08/09/2022, 12/13/2024, and 03/04/2025

Timing and execution details are not provided here; subsequent transactional reports (Forms 4 or broker confirmations) will show actual sales and proceeds.

Equity Markets Analyst

This is an administrative resale notice; it does not change Enliven's disclosed financials or guidance.

The filing names Jefferies LLC as the broker and shows an aggregate value line of $768,197.70 on the cover. That figure appears on the cover but the exact per-share sale prices are not listed.

Actual market impact depends on execution size and timing, neither of which are specified in this excerpt.

Key Figures

Shares offered: 18,054 shares Lot A (exercise date): 7,090 shares Lot B (exercise date): 3,000 shares +4 more

7 metrics

Shares offered 18,054 shares Total listed on Form 144 cover

Lot A (exercise date) 7,090 shares Exercise date <date>08/09/2022</date>

Lot B (exercise date) 3,000 shares Exercise date <date>12/13/2024</date>

Lot C (exercise date) 7,964 shares Exercise date <date>03/04/2025</date>

Cover aggregate value $768,197.70 Aggregate value field shown on cover line

Broker-dealer Jefferies LLC Listed broker at 520 Madison Ave on cover

Form date 06/17/2026 Date shown on cover line

Key Terms

Form 144, Stock Option Exercise, Broker‑dealer (Jefferies LLC), Aggregate value

4 terms

Form 144 regulatory

"Filed to notify the SEC of proposed sale of restricted/affiliate securities"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Stock Option Exercise financial

"Entries showing shares tied to prior option exercise dates"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Broker‑dealer (Jefferies LLC) market

"Jefferies LLC 520 Madison Ave listed as the broker on the cover line"

Aggregate value financial

"Cover line shows a numeric field of 768197.70 likely representing dollar value"

FAQ

What does Enliven Therapeutics (ELVN) Form 144 report?

The Form 144 reports a proposed resale of 18,054 shares of Common Stock through Jefferies LLC dated 06/17/2026. It lists three lots tied to prior option exercises on 08/09/2022, 12/13/2024, and 03/04/2025.

Who is handling the sale listed on ELVN's Form 144?

Jefferies LLC at 520 Madison Ave is named as the broker-dealer on the filing. The document identifies brokerage execution but does not show trade execution details or settlement information.

How many shares from option exercises are included in the Form 144?

The filing lists three exercised-option lots: 7,090, 3,000, and 7,964 shares, totaling 18,054 shares. Each lot is tied to the exercise dates shown in the filing.

Does the Form 144 disclose sale prices or proceeds for ELVN?

The cover line shows an aggregate field of $768,197.70, but the filing excerpt does not itemize per-share sale prices or confirm final proceeds from executed trades.

Will this Form 144 itself complete the sale of shares for ELVN?

No. The Form 144 is a notice of proposed resale by an affiliate; actual sales occur when trades execute through the broker, which would be reported separately if required by applicable rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 04:24 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001882764
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	6200 LOOKOUT ROAD BOULDER COLORADO 80301
Phone	720-647-8519
Name of Person for Whose Account the Securities are To Be Sold	Hohl Benjamin
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	18054	768197.70	60900000	06/17/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/09/2022	Stock Option Exercise	Enliven Therapeutics			7090	08/09/2022	N/A
Common	12/13/2024	Previously Exercised Stock Option	Enliven Therapeutics			3000	12/13/2024	N/A
Common	03/04/2025	Previously Exercised Stock Option	Enliven Therapeutics			7964	03/04/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 3/18/2026 and all representations regarding material non-public information were made as of the adoption of the plan.
Date of Notice	06/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Benjamin Hohl
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)